tetano
Editor, Senior Moderator
Influenza Other Respir Viruses. 2016 Feb 17. doi: 10.1111/irv.12377. [Epub ahead of print]
[h=1]ECDC expert opinion on efficacy and effectiveness of neuraminidase inhibitors published for public consultation.[/h] Penttinen P[SUP]1[/SUP], Catchpole M[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Neuraminidase inhibitors (NAI) are generally recommended for patients with severe or progressive influenza requiring hospitalisation in Europe. According to a recent survey by the VENICE initiative funded by the European Centre for Disease Prevention and Control (ECDC), national recommendations regarding influenza antiviral use are available in 24 EU/EEA Member States. These recommendations are generally in line with ECDC guidance developed for the 2009 pandemic [1]. Fourteen EU/EEA Member States also recommend use in residents of nursing homes or other long-term care facilities at risk of severe disease. Only a minority of EU/EEA Member States recommend antivirals as treatment or prophylaxis for outpatients who have a higher risk of severe outcomes of influenza (young children, elderly or individuals of any age with underlying chronic illnesses). This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
PMID: 26889767 [PubMed - as supplied by publisher]
[h=1]ECDC expert opinion on efficacy and effectiveness of neuraminidase inhibitors published for public consultation.[/h] Penttinen P[SUP]1[/SUP], Catchpole M[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Neuraminidase inhibitors (NAI) are generally recommended for patients with severe or progressive influenza requiring hospitalisation in Europe. According to a recent survey by the VENICE initiative funded by the European Centre for Disease Prevention and Control (ECDC), national recommendations regarding influenza antiviral use are available in 24 EU/EEA Member States. These recommendations are generally in line with ECDC guidance developed for the 2009 pandemic [1]. Fourteen EU/EEA Member States also recommend use in residents of nursing homes or other long-term care facilities at risk of severe disease. Only a minority of EU/EEA Member States recommend antivirals as treatment or prophylaxis for outpatients who have a higher risk of severe outcomes of influenza (young children, elderly or individuals of any age with underlying chronic illnesses). This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
PMID: 26889767 [PubMed - as supplied by publisher]